ExploreWatchlistsPricing
  1. JP-listed companies
  2. SanBio Company Limited
  3. Financials
  4. Stockholders' equity

SanBio Company Limited (4592)

Market cap
¥156.2B
P/E ratio
-27.7x
SanBio develops cell therapy drugs to help patients recover brain and nervous system functions lost due to injury or diseases like Parkinson's and Alzheimer's.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Jan 31, 202613,605+671.71%
Jan 31, 20251,763-36.87%
Jan 31, 20242,792-36.95%
Jan 31, 20234,429+117.62%
Jan 31, 20222,035-75.63%
Jan 31, 20218,350-23.61%
Jan 31, 202010,930+22.69%
Jan 31, 20198,909+944.14%
Jan 31, 2018853-81.43%
Jan 31, 20174,595-27.83%
Jan 31, 20166,367-7393.18%
Jan 31, 2015-87-95.55%
Jan 31, 2014-1,963

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat